David A. SinclairPhD · Professor of Genetics, Harvard Medical School
Still defends it
What it rests onHis own 2003 work and subsequent research, plus a formulation argument about fat solubility.
Source: lifespanpodcast.com ↗
Crossfire
Is resveratrol worth taking?
What the experts say
David A. SinclairPhD · Professor of Genetics, Harvard Medical School
Matt KaeberleinPhD · biogerontologist
Calls it a myth
What it rests onA failed replication in his own laboratory, and the subsequent history of the compound in human trials.
Source: podcasters.spotify.com ↗
Overview
Neither is talking about a specific population. This is a dispute about whether a molecule does what one of them said it does, and who is asking barely changes the answer.
Where they agree
Both accept that the Sirtris programme failed and that SRT501 was discontinued. They disagree about what that failure was a failure of.
What would settle it
Little would, which is worth saying out loud rather than pretending the question is live. This is a twenty-year-old dispute with a commercial history, a failed drug programme and a failed replication behind it. The honest framing is that one of these two is describing a scientific consensus and the other is describing his own position within it.
Practice does not pick a winner here
You do, and your call is dated, kept, and yours to change. Follow the people you already trust and what they publish turns into a short daily practice.
- Record where you land on this, and change your mind later without losing the history
- The 1 practice that follow from this question, graded and linked to the source
- Everything else these people publish, read and graded, in one place
Free to sign up and use. We do not ask for a card.